

[120] ORAMED PHARMACEUTICALS

Nadav Kidron¹, Josh Hexter^{2, 1} Oramed Pharmaceuticals, ² Oramed

- **Investment Rational**

Oramed Pharmaceuticals: Oral Insulin and the Future of Diabetes Care

Investment Rational

Oramed Pharmaceuticals has developed a proprietary platform technology for the oral delivery of injectable medications. Its flagship product, oral insulin, successfully completed Phase IIb trials under the FDA. Oramed has signed a \$50mm licensing deal with Chinese company HTIT for rights to oral insulin in Greater China. Oramed has a strong management team, backed by an international scientific advisory board.

- **Business Strategy**

Core Technology

What is the technology, its uniqueness and its value proposition

Oramed Pharmaceuticals' POD™ (Protein Oral Delivery) technology is designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. By preventing protein-drug breakdown in the gastrointestinal tract and promoting its crossing into the small intestine, this breakthrough solution brings oral protein-drug delivery closer to reality.

- **Product Profile/Pipeline**

Currently in the Oramed pipeline:

- ORMD-0801 (oral insulin) for diabetes (type 1 and 2) in late-stage P2 studies and NASH in an exploratory human trial
- ORMD-0901 (GLP-1) for diabetes in P1/2 PK study. Expect initiation of P2 study Q4, 2018.

Discussions with big pharma to use the platform technology for other medications continues.

What's Next?

Following our meeting with the FDA, we are initiating a 90-day HbA1c trial under an FDA IND for ORMD-0801. We anticipate the initiation of a Phase 2 study for ORMD-0901 in the United States in 2018. The current cash position (\$40mm) and low operation costs allows Oramed to efficiently continue its clinical development programs.